Our results expand on similar findings in non-HF patients with type 2 diabetes treated with SGLT2 inhibitors14–16 and are consistent with changes in markers of systemic iron metabolism after 12 months’ exposure to dapagliflozin in a recent analysis from the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study20. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.